StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
EHC$106.10+0.00%
Fair $106.10+0.0%

EHC

Encompass Health Corporation

Healthcare / Medical Care FacilitiesNYSE

$106.10

+0.00 (+0.00%)

Fairly Valued+0.0%Fair Value $106.10Fund rank 28/100 · Data gapFallback financials|
SA 20/D
F-Score: 4/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 25% · confianza 25%

FCF escenarios

weak_data · normalized FCF n/d · quality 50.0/100

Data gap 28/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 53/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

20/100

D

Piotroski

4/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

20/100

SEC 0%

Latest source: unknownPeriods: 18Warnings: 0unknown: 18
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · EHCLocal privado en este navegador · Encompass Health Corporation
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$10.5B

P/E

N/A

•

EV/EBITDA

N/A

•

ROE

23.2%

↑

Gross Margin

N/A

•

Debt/Equity

N/A

•
No hay histórico de precio usable para pintar el gráfico TradingView.

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2008–2025 · 17 años de histórico normalizado

Revenue CAGR

—

FCF CAGR

—

FCF margin

—

FCF / Net income

—

Latest source

Provider fallback

Margin decomposition

Último año: revenue $5.94B · net income $566.2M · FCF —

2008-FY → 2025-FY

Gross margin

—— pts

Operating margin

—— pts

Net margin

9.5%— pts

FCF margin

—— pts
MetricTTM
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
Income Statement
Revenue$5.94B$5.94B$5.37B$4.80B$4.35B$4.01B$3.57B$4.61B$4.28B$3.91B$3.64B————————
Net Income$566.2M$566.2M$455.7M$352.0M$271.0M$412.2M$284.2M$358.7M$292.3M$271.1M$247.6M$183.1M$222.0M$323.6M$185.0M$208.7M$899.0M$94.8M$252.4M
EBITDA————$783.1M$779.2M$766.9M$830.8M$754.9M$762.1M$760.7M$625.4M———————
EPS5.545.544.463.472.704.112.853.612.932.842.591.912.292.581.671.968.280.772.62
Operating Margin————12.4%13.9%15.8%13.3%13.0%14.8%16.1%————————
Net Margin9.5%9.5%8.5%7.3%6.2%10.3%8.0%7.8%6.8%6.9%6.8%————————
Balance Sheet
Debt/Equity———————————————10.56-17.57-1.83—
Cash Flow
Free Cash Flow————$141.0M$191.2M$311.9M$262.9M$507.9M$432.5M$462.5M$373.6M$274.0M$275.1M$270.7M$242.4M$268.2M$342.8M$171.5M
Returns
ROE23.2%23.2%22.0%21.4%20.7%21.6%17.9%26.5%22.9%23.5%33.6%29.9%46.9%93.9%63.6%178.4%-1055.2%-10.6%-23.2%
Growth & Yield
Revenue Growth10.5%10.5%11.9%10.4%8.3%12.6%-22.6%7.7%9.3%7.4%—————————
EPS Growth24.2%24.2%28.5%28.5%-34.3%44.2%-21.1%23.2%3.2%9.7%35.6%-16.6%-11.2%54.5%-14.8%-76.3%975.3%-70.6%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

19.3%

exigente

EPS terminal req.

$9.41

Spread vs growth

4.9%

5Y implied EPS CAGR

15.5%

exigente

EPS terminal req.

$11.39

Spread vs growth

8.7%

10Y implied EPS CAGR

12.7%

razonable

EPS terminal req.

$18.35

Spread vs growth

11.5%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · available periodreconcilia total n/d
Return attribution requires positive start and end prices.

Unavailable: positive start/end prices are required.